EBITDA: Income before interest, taxes, depreciation and amortization.
Sana Biotechnology, Inc. (SANA) had EBITDA of $-46.22M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-47.21M |
|
-- |
|
-- |
|
$48.61M |
|
$-48.61M |
|
$1.40M |
|
$-47.21M |
|
$-47.21M |
|
$-47.21M |
|
$-47.21M |
|
$-47.21M |
|
$-47.21M |
|
$-48.61M |
|
|
EBITDA |
$-46.22M |
276.86M |
|
276.86M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$111.69M |
|
$25.67M |
|
$261.90M |
|
$373.59M |
|
$86.27M |
|
-- |
|
$168.09M |
|
$254.35M |
|
$119.24M |
|
$-80.58M |
|
$119.24M |
|
269.82M |
|
| Cash Flow Statement Financials | |
$-37.38M |
|
$49.44M |
|
$-0.13M |
|
$76.06M |
|
$88.00M |
|
$11.93M |
|
$5.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-39.59% |
|
58.59% |
|
-12.64% |
|
-39.59% |
|
$0.44 |
|
$-0.14 |
|
$-0.14 |
|